Objectives: This study was performed to investigate the activity of tamoxifen, an antioestrogen widely used in the treatment of breast cancer, against Leishmania.
Introduction
Human leishmaniasis is an endemic disease in 88 countries distributed in tropical and subtropical regions of the world. Clinical manifestations of this parasitic illness vary from self-healing cutaneous ulcers to very aggressive and disfiguring cases of diffuse or mucocutaneous diseases or to the life-threatening visceral form. More than 90% of cutaneous leishmaniasis cases occur in Iran, Afghanistan, Syria, Saudi Arabia, Brazil and Peru. 1 In Brazil, Leishmania (Viannia) braziliensis is the most common agent for cutaneous and mucocutaneous leishmaniasis, whereas Leishmania (Leishmania) amazonensis is the most important causative agent of the diffuse form of the disease. Chemotherapy of leishmaniasis relies mainly on the administration of pentavalent antimonials that are toxic and poorly tolerated, require daily injections and are becoming ineffective due to the proliferation of resistant parasites. 2, 3 Therefore, alternative drugs are in pressing need.
Leishmania life cycle consists of two distinct forms: promastigotes, flagellated extracellular parasites of the digestive tract of sand flies, and amastigotes, non-flagellated, non-motile stages that live inside parasitophorous vacuoles (PVs) in macrophages of mammalian hosts. The PV encloses a strongly hydrolytic, acid environment-pH around 5.0-and the amastigote does not attenuate this hostile milieu. 4 -6 Amastigotes have been shown to carry out vital processes (i.e. cellular respiration, nutrient uptake and DNA and RNA synthesis) under these conditions. 7 Tamoxifen is a triphenylethylene widely used in the treatment and in the prevention of breast cancer due to its activity as an oestrogen receptor modulator. 8 However, it has become evident that many biological effects of tamoxifen are independent of the oestrogen machinery, such as modulation of calmodulin, caspases and kinases, 9 interference in ceramide metabolism, 10, 11 inhibition of the acidification of intracellular organelles 12 -14 and partitioning into lipids where it exerts membrane fluidizing and antioxidant activities. 15 While oestrogen receptor modulated responses have not been described in Leishmania, some of the effects observed with tumour cell lines suggested a potential activity of tamoxifen against these parasites. Particularly interesting to us were the findings of Altan et al. 13 showing that adriamycin resistance in breast cancer cells was reversed by tamoxifen as a result of the redistribution of cellular adriamycin from acidic organelles to the nucleus. These authors established that tamoxifen was able to inhibit the acidification of organelles in several cell types in an oestrogen-independent way. Since Leishmania amastigotes are well adapted to survive in acidic PV, it seemed plausible to test the activity of tamoxifen against these parasites. In this paper, we describe the activity of tamoxifen against promastigotes and amastigotes of Leishmania in vitro. We also show that tamoxifen is able to modify the intravacuolar pH of L. (L.) amazonensis-infected macrophages inducing a state where the drug activity against the parasite is increased. ) amazonensis amastigotes were obtained from experimentally infected BALB/c mice as described previously. 16 Amastigotes purified from lesions were kept at 338C in RPMI 1640 medium (Invitrogen) supplemented with 10% FCS in an atmosphere of 5% CO 2 . Parasites retained the typical amastigote morphology and were viable in these conditions for at least 48 h.
Materials and methods

Cells
Resident peritoneal macrophages were obtained by peritoneal lavage of 25-to 30-day-old female BALB/c mice with 3-5 mL of RPMI 1640 medium repeated three times. The collected cell suspension was centrifuged at 300 g for 10 min at 48C, the pellet was resuspended in RPMI 1640 medium supplemented with 10% FCS and gentamicin 50 mg/L and cultivated at 378C in an atmosphere of 5% CO 2 .
The continuous line of human foreskin fibroblasts (HFF) was grown in RPMI 1640 supplemented with 10% FCS and cultivated at 378C in an atmosphere of 5% CO 2 .
Drugs
Tamoxifen, 17b-oestradiol and amphotericin B were purchased from Sigma-Aldrich, St Louis, MO, USA. Stock solutions of tamoxifen and 17b-oestradiol were prepared in ethanol and amphotericin B stock was prepared in DMSO (5 mM final concentration). Tamoxifen and amphotericin B were stored at 2208C and 17b-oestradiol at room temperature.
In vitro antiproliferative activity assays
Cell viability was evaluated in vitro by cultivating promastigotes (5Â10 6 ) or amastigotes ( 1Â10 7 ) in 199 medium or RPMI 1640, respectively. Parasites were incubated in the presence of increasing concentrations of tamoxifen (2.5-30 mM), amphotericin B (as a control drug, 0.05 -0.30 mM) or 17b-oestradiol in 24-well culture dishes (Corning Life Sciences, Corning, NY, USA) for 24 h. Quantification of viable cells was assessed either by cell counting or by measuring the cleavage of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT; Sigma-Aldrich) by metabolically active cells as described previously. 17 In brief, cells were incubated in 3-(N-morpholino) propanesulfonic acid (MOPS)-buffered saline [30 mM MOPS ( pH 7.2), 116 mM NaCl, 5.4 mM KCl, 0.8 mM MgSO 4 , 5.5 mM D-glucose] containing MTT 5 mg/mL for 2 h (at 258C for promastigotes and 338C for amastigotes). MTT cleavage was assessed by using a multiwell scanning spectrophotometer (Labsystems; Multiskan EX) with a reference wavelength of 690 nm and a test wavelength of 595 nm. Assays were performed in triplicate and results are expressed as the mean percentage reduction of parasite numbers compared with untreated control wells calculated for at least three independent experiments. The 50% and 90% inhibitory concentrations (IC 50 and IC 90 ) were determined from sigmoidal regression of the concentration-response curves using Scientific Graphing and Analysis Software ORIGIN 7.5.
Alternatively, cell viability and growth was analysed by incubating promastigotes (5Â10 6 ) in the presence of increasing concentrations of tamoxifen for 24 h; parasites were then washed in PBS [10 mM Na 2 PO 4 , 1.76 mM KH 2 PO 4 ( pH 7.4), 137 mM NaCl and 2.7 mM KCl] and grown in 199 medium for additional 24 h in the absence of drug. At the end of this period, cell density was determined by counting aliquots of the cultures in a haemocytometer.
In vitro cytotoxicity was evaluated by cultivating 5Â10 5 HFF in 24-well plates for 24 h in the presence of increasing concentrations of tamoxifen (5-80 mM). Cell viability was assessed by the MTT assay as described above and results are expressed as percentage reduction in cell viability compared with untreated control cultures. The 50% cytotoxic concentration (CC 50 ) was determined as described above for IC 50 values.
Drug activity against intracellular amastigotes
Killing of intracellular L. (L.) amazonensis amastigotes was assayed by analyses of the number of infected cells in macrophage monolayers. Peritoneal macrophages were plated on round glass coverslips inside the wells of 24-well culture dishes, at a density of 4Â10 5 cells per coverslip, in RPMI 1640 supplemented with 10% FCS and gentamicin 50 mg/L. After 2 h of incubation at 378C in an atmosphere of 5% CO 2 , L. (L.) amazonensis stationary-phase promastigotes (in a ratio of 7 parasites : 1 macrophage) or lesion-derived amastigotes (1:1) were added to the wells and the cultures were incubated at 338C in a 5% CO 2 atmosphere. After 3 h, parasites were removed by extensive washing with RPMI medium without FCS and infected cultures were treated with increasing concentrations of tamoxifen (5-20 mM) or amphotericin B (0.01 -0.30 mM) for 48 h or with ammonium chloride (NH 4 Cl, 5 or 10 mM) for 24 h. The monolayers were washed, fixed and stained with the Instant Prov kit (Newprov, Pinhais, Brazil). The percentage of infected macrophages was assessed by light microscopy observation by counting 100 cells in triplicate coverslips. IC 50 and IC 90 were calculated from data obtained in three independent experiments.
Intravacuolar pH alterations in response to tamoxifen
Intracellular and intravacuolar pH were evaluated using two different fluorescent probes: SNAFL-calcein and Acridine Orange (AO) (Sigma-Aldrich).
Peritoneal BALB/c macrophages ( 8Â10 5 ) were cultivated on 0.15 mm thick coverslips in Delta T dishes (Bioptechs, Butler, PA, USA) in RPMI 1640 medium at 378C in a 5% CO 2 atmosphere. After 3 h, amastigotes of L. (L.) amazonensis purified from mice lesions were used for in vitro macrophage infections. Infected cultures were kept at 338C in a 5% CO 2 atmosphere and samples were treated with 10 mM tamoxifen, ethanol (0.25%) or left untreated. Cells were loaded with the pH-sensitive ratiometric probe SNAFL-calcein (Molecular Probes). 18 Experiments were performed as previously described. 19 Lasersharp software version 3.2 TC was used for image acquisition and basic processing.
Peritoneal BALB/c macrophages, plated on round glass coverslips as described above, were infected with L. ) were incubated in RPMI medium pH 4.5 or 7.5 supplemented with 5% FCS for 4 or 24 h in the absence or in the presence of increasing concentrations of tamoxifen. Quantification of cell growth was evaluated by counting aliquots of the cultures in a haemocytometer.
Results
Activity of tamoxifen against Leishmania in vitro
Tamoxifen was tested for its effect on the viability of L. (L.) amazonensis promastigotes in vitro. Cell viability, evaluated through MTT cleavage, decreased as a function of drug concentration. After 24 h of incubation, the calculated IC 50 against L. (L.) amazonensis was 16.4+0.2 mM ( Table 1) . As a control, activity of amphotericin B against L. amazonensis promastigotes was calculated as being 0.15+0.06 mM, in agreement with previously published data. 20 These results were confirmed by cell counting. The effect of tamoxifen was irreversible since parasites incubated with the drug and left in normal culture media for 24 h did not recover (data not shown).
The activity of tamoxifen against other Leishmania species was analysed by testing promastigotes of L. Table 1 .
Viability of L. (L.) amazonensis amastigotes, obtained from lesions and axenically cultivated for 24 h at 338C, was also inhibited by tamoxifen at an IC 50 of 11.1+0.2 mM (Table 1) .
Cytotoxicity assays were performed treating HFF cultures with increasing concentrations of tamoxifen, allowing the determination of a CC 50 of 22.8+2.6 mM. Treatment of HFF or peritoneal macrophage cultures with 10 mM tamoxifen for 24 h resulted in 100% and 85% survival, respectively.
Effect of tamoxifen on intracellular amastigote survival
The activity of the drug against the parasite in the intracellular environment was tested by treating peritoneal BALB/c macrophage cultures infected with L. (L.) amazonensis. The IC 50 of tamoxifen against intracellular amastigotes was 5.46+0.12 mM and the IC 90 was calculated as 6.73 mM (Figure 1 and data amazonensis amastigotes which exhibited the same pattern of growth in the absence or in the presence of 17b-oestradiol while incubation with 17b-oestradiol did not modify the activity of tamoxifen (Figure 2) , confirming that the leishmanicidal activity of tamoxifen is independent of the oestrogen receptor machinery.
Intravacuolar pH alterations in response to tamoxifen
In vitro infections were analysed using non-invasive ratiometric confocal microscopy with dual-label SNAFL-calcein-AM probe before and after incubation with 10 mM tamoxifen. SNAFL-calcein-AM compartmentalizes into acid vacuoles and the fluorescence is emitted in distinct wavelengths according to H þ concentrations-the more acidic the intravacuolar pH, the greener the organelle appears, whereas a more alkaline environment appear in tones towards red. As shown in Figure 3 , images were obtained by merging the 550 and 640 nm emission channels. In infected and untreated macrophages, SNAFLcalcein-AM was detected mainly as yellow and green granules concentrated in the PV. Upon addition of tamoxifen and as incubation time elapsed, detection of SNAFL-calcein-AM in PVs was more intense in the 640 nm emission channel, resulting in red fluorescence (Figure 3 ). This suggested a rapid alkalinization of the PVs, detectable as soon as 10 min after drug addition. The presence of parasites inside PVs was confirmed by the phase contrast images also shown in Figure 4 . Infected macrophages treated with 10 mM tamoxifen for 24 h and incubated with SNAFL-calcein-AM exhibited large vacuoles devoid of amastigotes and more alkaline than PVs in untreated cells (data not shown).
Measurements of intravacuolar pH were also carried out in infected macrophages treated with ethanol in the concentration necessary to deliver the highest tamoxifen concentration used in the tests. Changes in pH were not observed in these cells (data not shown) indicating that the effect obtained with tamoxifen was not due to the drug diluent.
These findings were therefore consistent with the hypothesis of reduced acidification of intracellular compartments induced by tamoxifen, previously observed in other systems.
The effect of tamoxifen on intravacuolar acidification was also tested labelling peritoneal BALB/c macrophages infected with L. (L.) amazonensis amastigotes with AO, a weakly basic fluorescent probe. AO is taken up by living cells and accumulates in acidic compartments. Fluorescence of AO is green at low concentrations, whereas at high concentrations the fluorescence changes to orange. 21 Nuclei in infected or non-infected cells (Figure 4a and i) stained green. In the cytoplasm of infected cells, AO accumulated inside vacuoles containing amastigotes resulting in red fluorescence (Figure 4a ). Upon addition of 10 mM tamoxifen for 30 min, a decrease of the red AO fluorescence was observed in PVs of infected cells (Figure 4b ). To verify whether this effect was lasting, infected macrophages treated with tamoxifen for 30 min were washed and kept at 338C for 30 min, 4 or 24 h in culture media without drug (Figure  4c -e) . Cells were then stained with AO for 10 min and examined. The pH in PVs of infected macrophages remained alkaline, even 24 h after drug removal, indicating that tamoxifen's effect on these cells was probably irreversible.
Tamoxifen's alkalinizing effect was not exclusive to infected cells, since non-infected macrophages also showed a remarkable reduction of orange-stained microvesicles (Figure 4i and j) .
Alkalinization of the PV is not sufficient to control the infection
To verify whether parasites were killed by tamoxifen's direct action or by an indirect effect of the drug on the host cell, two different approaches were taken. The alkalinizing agent NH 4 Cl was used to treat infected macrophages for 30 min, 4 or 24 h. As expected, 5 or 10 mM NH 4 Table 2 ), indicating that the alkaline PV is not sufficient to arrest the infection.
The second approach used to test whether tamoxifen's direct effect was required was to pre-treat uninfected macrophage cultures with tamoxifen for 24 h. Cells were then washed, infected and the cultures were grown for additional 24 h in the absence of tamoxifen. Pre-treated macrophages were as permissive to the infection as naive cells and there was no reduction in the percentage of infection compared with control untreated cells ( Table 2 ), indicating that tamoxifen is directly active against the intracellular parasite.
Tamoxifen's activity is increased at neutral pH
To verify whether a neutral -alkaline pH in the PV would have any impact on drug activity, promastigotes and freshly lesionpurified amastigotes were submitted to tamoxifen treatment for 4 and 24 h at pH 4.5 or 7.5. A striking increase in drug activity was observed against promastigotes grown at pH 7.5 as compared with cultures kept at pH 4.5 (Figure 5a and b) . A less pronounced but nonetheless clear increase in effect was also observed against amastigotes kept at neutral pH conditions (Figure 5c and d) . The increased parasite killing at neutral pHs was not due to the pH itself since, after 4 and 24 h, both control promastigotes and amastigotes, grown in the absence of drugs, maintained unaltered their metabolic rate and viability in either pH as judged by similar optical densities in the MTT test (data not shown).
This confirms that tamoxifen, with a pK a of 6.9, is more effective in its neutral form, attained at neutral and alkaline pHs. Consequently, activity against intracellular amastigotes is probably intensified by the increase in PV pH verified after addition of tamoxifen.
Discussion
We have shown that tamoxifen is effective against Leishmania. Susceptibility of microorganisms to tamoxifen in vitro has only been described for Candida albicans 22 and Coccidioides immitis. 23 There are, as yet, no reports available regarding the activity of tamoxifen against protozoan parasites.
The effect of tamoxifen against Leishmania is remarkable, given the absence of response to oestrogen in these organisms. On the other hand, several studies have reported biological properties of tamoxifen that cannot be explained by oestrogen receptor binding, such as the inhibition of acidification of organelles reported in tumour cells.
14 Using resident peritoneal macrophages, we demonstrated that 10 mM tamoxifen reduced parasitism by more than 90% in 24 h. We have also shown that PVs of L. (L.) amazonensis-infected macrophages undergo a rapid pH shift upon addition of tamoxifen.
The rapid change in PV pH, however, is not directly responsible for killing amastigotes, as shown by the evaluation of parasite survival in pH 4.5 or 7.5. It does, however, have a major impact on tamoxifen's effectiveness against the parasite. That is most likely explained by the properties of tamoxifen: the neutral molecule partitions into the membrane and flips more easily into the interior than would the charged molecule. It is tempting to speculate that, once inside the acid PV, tamoxifen gets protonated, the pH shifts and this is followed by an increase in the influx of Cl 2 , as shown in microsomes isolated from MCF-7/ ADR cells.
14 That would bring about the regeneration of neutral tamoxifen that may now combine with the amastigote membrane.
Besides the ability to accumulate in the lipid phase, tamoxifen has also been shown to be a potent inhibitor of ATPdependent membrane acid transport. 24, 25 Vacuoles containing Leishmania are rapidly acidified and reach pH 5.0 in ,30 min after phagocytosis. 26 The acidic luminal pH is sustained by a vacuolar H þ -ATPase of macrophage origin in the PV membrane. Amastigotes also express a P-type H þ -ATPase in their plasma membrane and may take part in the PV acidification. 27 This P-type H þ -ATPase is vital for the parasite to maintain a neutral internal pH. 28 H þ ATPases both at the PV membrane and at the amastigote surface could be the targets of tamoxifen's action resulting initially in vacuole alkalinization followed by disruption of the ionic metabolic steady-state of the parasite. Omeprazole, a potent ATPase inhibitor at acidic pHs, has been suggested as a potential antileishmanial drug. It has been shown to kill intracellular L. donovani in vitro through inhibition of the parasite K þ , H þ ATPase. 29 Interestingly, not only intracellular amastigotes were killed by tamoxifen but also extracellular promastigotes. In fact, we showed that tamoxifen inhibits the survival of promastigotes of a wide range of Leishmania species, aetiological agents of distinct clinical forms of leishmaniasis, in a low micromolar concentration range. Plasma membrane P-type H þ ATPases have also been shown to regulate intracellular pH in L. (L.) amazonensis promastigotes. 30 Further studies are needed to verify whether tamoxifen's mechanism of action against Leishmania depends on ATPase inhibition. Tamoxifen is highly lipophilic and has been shown to be strongly incorporated in biomembranes, reported to disrupt the structure of model and artificial membranes and to induce the permeabilization of mitochondria. 31 It is also possible, therefore, that the effect on Leishmania is derived from drug partition into the parasite membranes. It has been observed that the partition of tamoxifen into membranes is modulated by several factors, including membrane composition: for example, partition of tamoxifen into membranes decreases as cholesterol concentration is raised. 32 Leishmania do not synthesize cholesterol. Ergosterol makes up the main sterol in the plasma membrane in these parasites. 33 Amastigotes have been shown to be able to incorporate cholesterol from their hosts but they are also able to synthesize ergosterol (D. C. Arruda and S. R. B. Uliana, unpublished results). Distinct parasite and host cell membrane compositions could result in preferential partitioning into the parasite's membrane. Further studies are necessary to verify whether tamoxifen is indeed incorporated into Leishmania membranes and if the presence of ergosterol favours the partition of tamoxifen. Breast cancer accounts for 31% of all incident cancers in women in North America. It is estimated that more than 214 000 new cases of breast cancer were diagnosed in the USA in 2005 34 and tamoxifen represents the cornerstone of breast cancer treatment in women with tumours bearing hormone receptors. Since these patients are treated with tamoxifen for at least 5 years, much clinical experience has been gained on the safety and undesirable effects of the drug. Tamoxifen is well tolerated and side effects, of which the most serious is an increased risk for endometrial cancer, appear only after prolonged use. The doses usually administered for the treatment of breast cancer, of 20 mg/kg body weight, achieve serum concentrations of 0.2 -0.8 mM. 35, 36 Due to the high hydrophobicity of tamoxifen, in human tissues concentrations are 10-to 60-fold higher than in serum, with particularly high levels detected in the liver and lung. 37 Tamoxifen also accumulates in the skin and bone tissue. 37 This distribution pattern is relevant considering parasite localization in cutaneous and visceral leishmaniasis. Tissue concentrations attainable with currently used regimens are at least equivalent to the effective concentrations that kill Leishmania intracellular amastigotes in our study. Furthermore, it is to be expected that antileishmanial therapy with tamoxifen would not require such prolonged use. In conclusion, our results suggest that tamoxifen has a great potential to be tested as a therapeutic agent against leishmaniasis.
